FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3120366265> ?p ?o ?g. }

• W3120366265 abstract "Abstract Background There is limited evidence on the modification or stopping of antiretroviral therapy (ART) regimens, including novel antiretroviral drugs. The aim of this study was to evaluate the discontinuation of first ART before and after the availability of better tolerated and less complex regimens by comparing the frequency, reasons and associations with patient characteristics. Methods A total of 3019 ART-naive patients registered in the HIV-TR cohort who started ART between Jan 2011 and Feb 2017 were studied. Only the first modification within the first year of treatment for each patient was included in the analyses. Reasons were classified as listed in the coded form in the web-based database. Cumulative incidences were analysed using competing risk function and factors associated with discontinuation of the ART regimen were examined using Cox proportional hazards models and Fine-Gray competing risk regression models. Results The initial ART regimen was discontinued in 351 out of 3019 eligible patients (11.6%) within the first year. The main reason for discontinuation was intolerance/toxicity (45.0%), followed by treatment simplification (9.7%), patient willingness (7.4%), poor compliance (7.1%), prevention of future toxicities (6.0%), virologic failure (5.4%), and provider preference (5.4%). Non-nucleoside reverse transcriptase inhibitor (NNRTI)-based (aHR = 4.4, [95% CI 3.0–6.4]; p < 0.0001) or protease inhibitor (PI)-based regimens (aHR = 4.3, [95% CI 3.1–6.0]; p < 0.0001) relative to integrase strand transfer inhibitor (InSTI)-based regimens were significantly associated with ART discontinuation. ART initiated at a later period (2015-Feb 2017) (aHR = 0.6, [95% CI 0.4–0.9]; p < 0.0001) was less likely to be discontinued. A lower rate of treatment discontinuation for intolerance/toxicity was observed with InSTI-based regimens (2.0%) than with NNRTI- (6.6%) and PI-based regimens (7.5%) (p < 0.001). The percentage of patients who achieved HIV RNA < 200 copies/mL within 12 months of ART initiation was 91% in the ART discontinued group vs. 94% in the continued group (p > 0.05). Conclusion ART discontinuation due to intolerance/toxicity and virologic failure decreased over time. InSTI-based regimens were less likely to be discontinued than PI- and NNRTI-based ART." @default.
• W3120366265 created "2021-01-18" @default.
• W3120366265 creator A5005292421 @default.
• W3120366265 creator A5005868435 @default.
• W3120366265 creator A5015860848 @default.
• W3120366265 creator A5019778058 @default.
• W3120366265 creator A5023483386 @default.
• W3120366265 creator A5049167936 @default.
• W3120366265 creator A5055479335 @default.
• W3120366265 creator A5061998389 @default.
• W3120366265 creator A5063746293 @default.
• W3120366265 creator A5076731264 @default.
• W3120366265 creator A5082473228 @default.
• W3120366265 creator A5082977113 @default.
• W3120366265 creator A5083140876 @default.
• W3120366265 date "2021-01-09" @default.
• W3120366265 modified "2023-10-18" @default.
• W3120366265 title "Trends and factors associated with modification or discontinuation of the initial antiretroviral regimen during the first year of treatment in the Turkish HIV-TR Cohort, 2011–2017" @default.
• W3120366265 cites W1416208575 @default.
• W3120366265 cites W1494300042 @default.
• W3120366265 cites W1893469951 @default.
• W3120366265 cites W2005430618 @default.
• W3120366265 cites W2017286834 @default.
• W3120366265 cites W2019694480 @default.
• W3120366265 cites W2038981426 @default.
• W3120366265 cites W2066985929 @default.
• W3120366265 cites W2082405872 @default.
• W3120366265 cites W2096154076 @default.
• W3120366265 cites W2111327516 @default.
• W3120366265 cites W2121737909 @default.
• W3120366265 cites W2134537454 @default.
• W3120366265 cites W2136381344 @default.
• W3120366265 cites W2147414018 @default.
• W3120366265 cites W2156085525 @default.
• W3120366265 cites W2169767760 @default.
• W3120366265 cites W2280151931 @default.
• W3120366265 cites W2318289184 @default.
• W3120366265 cites W2510140996 @default.
• W3120366265 cites W2584986959 @default.
• W3120366265 cites W2760575381 @default.
• W3120366265 cites W2774674623 @default.
• W3120366265 cites W3025504664 @default.
• W3120366265 cites W3040077900 @default.
• W3120366265 cites W4240243247 @default.
• W3120366265 doi "https://doi.org/10.1186/s12981-020-00328-6" @default.
• W3120366265 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7796577" @default.
• W3120366265 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33422112" @default.
• W3120366265 hasPublicationYear "2021" @default.
• W3120366265 type Work @default.
• W3120366265 sameAs 3120366265 @default.
• W3120366265 citedByCount "5" @default.
• W3120366265 countsByYear W31203662652022 @default.
• W3120366265 countsByYear W31203662652023 @default.
• W3120366265 crossrefType "journal-article" @default.
• W3120366265 hasAuthorship W3120366265A5005292421 @default.
• W3120366265 hasAuthorship W3120366265A5005868435 @default.
• W3120366265 hasAuthorship W3120366265A5015860848 @default.
• W3120366265 hasAuthorship W3120366265A5019778058 @default.
• W3120366265 hasAuthorship W3120366265A5023483386 @default.
• W3120366265 hasAuthorship W3120366265A5049167936 @default.
• W3120366265 hasAuthorship W3120366265A5055479335 @default.
• W3120366265 hasAuthorship W3120366265A5061998389 @default.
• W3120366265 hasAuthorship W3120366265A5063746293 @default.
• W3120366265 hasAuthorship W3120366265A5076731264 @default.
• W3120366265 hasAuthorship W3120366265A5082473228 @default.
• W3120366265 hasAuthorship W3120366265A5082977113 @default.
• W3120366265 hasAuthorship W3120366265A5083140876 @default.
• W3120366265 hasBestOaLocation W31203662651 @default.
• W3120366265 hasConcept C126322002 @default.
• W3120366265 hasConcept C142462285 @default.
• W3120366265 hasConcept C201903717 @default.
• W3120366265 hasConcept C203014093 @default.
• W3120366265 hasConcept C2777302000 @default.
• W3120366265 hasConcept C2778715236 @default.
• W3120366265 hasConcept C2781143361 @default.
• W3120366265 hasConcept C2781413609 @default.
• W3120366265 hasConcept C2993143319 @default.
• W3120366265 hasConcept C3013748606 @default.
• W3120366265 hasConcept C50382708 @default.
• W3120366265 hasConcept C71924100 @default.
• W3120366265 hasConcept C72563966 @default.
• W3120366265 hasConceptScore W3120366265C126322002 @default.
• W3120366265 hasConceptScore W3120366265C142462285 @default.
• W3120366265 hasConceptScore W3120366265C201903717 @default.
• W3120366265 hasConceptScore W3120366265C203014093 @default.
• W3120366265 hasConceptScore W3120366265C2777302000 @default.
• W3120366265 hasConceptScore W3120366265C2778715236 @default.
• W3120366265 hasConceptScore W3120366265C2781143361 @default.
• W3120366265 hasConceptScore W3120366265C2781413609 @default.
• W3120366265 hasConceptScore W3120366265C2993143319 @default.
• W3120366265 hasConceptScore W3120366265C3013748606 @default.
• W3120366265 hasConceptScore W3120366265C50382708 @default.
• W3120366265 hasConceptScore W3120366265C71924100 @default.
• W3120366265 hasConceptScore W3120366265C72563966 @default.
• W3120366265 hasFunder F4320308573 @default.
• W3120366265 hasIssue "1" @default.
• W3120366265 hasLocation W31203662651 @default.
• W3120366265 hasLocation W31203662652 @default.
• W3120366265 hasLocation W31203662653 @default.
• W3120366265 hasOpenAccess W3120366265 @default.

• next